Genomenon

Company profile

About Genomenon

Genomenon is a precision medicine and genomics company that transforms biomedical literature into actionable real-world evidence for biopharma companies and clinical diagnostic laboratories. The company addresses a critical challenge in genomics: the evidence needed to recognize diseases, classify genetic variants, and reach patients exists in published literature, but finding it across 11.2 million full-text articles and 3.7 million supplemental datasets is extraordinarily difficult. Genomenon's AI-powered platform reads every word of millions of articles and data sources, which scientists then analyze, structure, and curate to deliver traceable, regulatory-grade evidence at scale. For biopharma, Genomenon provides custom real-world evidence builds that support broader drug labels, identify more eligible patients, and create programs defensible to regulators. For clinical labs, the company offers Mastermind for germline variant interpretation and the Cancer Knowledgebase (CKB) for somatic variant interpretation, enabling faster case sign-outs, fewer variants of uncertain significance (VUS), and more confident diagnoses. The company also provides clinical diagnostic services including variant curation, interpretation, workflow optimization, and regulatory compliance support. Genomenon's three-step process—identify, structure, and curate—transforms hidden evidence into confident decisions, serving leading health systems, research institutions, and pharmaceutical companies globally.

Company description · Genomenon official website